Background: Cytokine-Induced Killer (CIK) cells are an attractive approach for cellular immunotherapy,
as they are capable of recognizing tumor cells without the need of antigen-specific
priming and can be efficiently and rapidly expanded in vitro. We previously demonstrated that CIK cells can exert ADCC when combined with clinical-grade
monoclonal antibodies [1]. In this study, we evaluated the efficacy of this combined
therapy in vivo in triple negative breast cancer (TNBC), an aggressive tumor that occurs in approximately
15% of all breast cancer patients. Women with TNBC cannot be treated with hormonal
treatments or molecular targeted therapies, as they lack the appropriate targets for
these drugs, and thus new therapeutic options are urgently needed.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P07.03
Identification
Copyright
© 2018 Published by Elsevier Inc.
